Lonza's Capital Markets Day 2018 Outlines Sustainable Growth Plans Through Focus and Investment
Lonza is holding a series of events as part of this year's Capital Markets Day from 24-26 September in Zurich and Visp (…
Lonza is holding a series of events as part of this year's Capital Markets Day from 24-26 September in Zurich and Visp (…
. • Outperformance in Pharma & Biotech in H1 2018 in sales, with margins up 270 bps, was combined with strong positi…
As a pre-information for the reporting of the Half-Year Results 2018 on 25 July, Lonza today is providing clarification…
Downstream processing is used to manufacture antibiotics, antibodies, hormones, vaccines and also used for the productio…
308 shareholders attended, representing 49.96% of the share capital Shareholders re-elected all existing members of the…
. • Continued strong demand for pharma offerings in Clinical Development and Manufacturing and Commercial Manufacturin…
On 22 March 2018 Lonza has published the invitation to the 2018 Annual General Meeting (AGM) and the Annual Report for t…
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients…
. • Annual General Meeting to take place on 4 May 2018 in Basel • Albert M. Baehny proposed as new Chairperson of the B…
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priori…